Breaking News

GBI Secures Commercial Manufacturing Contract

Master supply agreement is for commercializing a radioimmunoconjugate product.

GBI BioManufacturing, a contract development and manufacturing organization (CDMO), signed its second master supply agreement (MSA) for commercializing a radioimmunoconjugate product. “We are thrilled to announce the signing of our second commercial contract, a testament to the exceptional capabilities and unwavering commitment of the entire GBI team,” said Darrin Schellin, CEO. “This achievement highlights our expertise and experience in the radiopharmaceutical sector, and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters